D2A-Ala peptide derived from the urokinase receptor exerts anti-tumoural effects in vitro and in vivo
F Furlan, G Eden, M Archinti, R Arnaudova, G Andreotti… - Peptides, 2018 - Elsevier
D2A-Ala is a synthetic peptide that has been created by introducing mutations in the original
D2A sequence, 130 IQEGEEGRPKDDR 142 of human urokinase receptor (uPAR). In vitro,
D2A-Ala peptide displays strong anti-tumoural properties inhibiting EGF-induced …
D2A sequence, 130 IQEGEEGRPKDDR 142 of human urokinase receptor (uPAR). In vitro,
D2A-Ala peptide displays strong anti-tumoural properties inhibiting EGF-induced …
For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to ＞99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.
Quick Links:
Contact Information:
Eva He
eva@pepmic.com
Pepmic Co., Ltdeva@pepmic.com
www.pepmic.com
没有评论:
发表评论